MenOMVax – Meningococcal B vaccine

Neisseria meningitidis is a Gram-negative encapsulated bacterium that causes bacterial meningococcal meningitidis epidemics worldwide. Nearly all cases of meningococcal disease worldwide are caused by 6 of the 12 identified meningococcal serogroups: A, B, C, W, X, and Y. In particular, the serogroup B Neisseria meningitidis is the major cause of invasive meningococcal disease in Europe, North and South America, Canada, Australasia, most part of North Africa, and in other countries including China and Taiwan. The disease can be rapidly fatal and can leave severe disability, making treatment difficult. Survivors often suffer neurological impairments such as motor weakness, paralysis, in coordination and cognitive deficits. Loss of limbs due to hemorrhagic necrosis is also common.

Due to the fast escalation of symptoms, prompt treatment is often difficult, and vaccination remains a priority in order to tackle mortality, morbidity and sequelae.

Contraria Biotech will design and technically develop an affordable and sustainable vaccine that will harness the remarkable features of modified mOMV and will protect against the meningococcal B disease. The flexibility of the mOMV platform will also allow “plug and play” modifications and/or inclusion of new antigens to increase valency and coverage in response to epidemiological changes.

The vaccine will have low production costs and will be easy to scale-up for production and rapid commercialization.